BiotechTube

Imipenem+Relebactam

ApprovedWithdrawn
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Carbapenem-Resistant Enterobacteriaceae Infection

Conditions

Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections, Antibiotic Resistant Infection

Trial Timeline

Jun 7, 2021 → Jan 12, 2023

NCT ID
NCT04785924

About Imipenem+Relebactam

Imipenem+Relebactam is a approved stage product being developed by Merck for Carbapenem-Resistant Enterobacteriaceae Infection. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04785924. Target conditions include Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04785924ApprovedWithdrawn

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85